The US market was important for the British shoe supplier Dr. Martens Plc has long been a problem case. The company now sees itself on the right track there. This emerges from an interim statement published on Monday.
According to preliminary figures, Dr. Martens to 260 million British pounds (310 million euros) in the third quarter of 2024/25, which ended on December 29th. This means that it fell by three percent compared to the same period last year. However, adjusted for exchange rate changes, revenue increased by three percent.
In America, sales fell by four percent in the reporting currency, but increased by two percent after adjusting for currency effects. This was due not least to a currency-adjusted increase in sales of four percent in our own retail. “One of our key plans was to return our own retail in America to positive growth in the second half of the year. “We are on track,” emphasized the company.
In the EMEA region, which includes Europe, the Middle East and Africa, sales fell by four percent in the third quarter; adjusted for currency effects, they remained unchanged compared to the same period last year. In the Asia-Pacific region, revenue grew by six percent (+14 percent adjusted for currency effects).
Worldwide, sales in the company’s own retail sector fell by five percent (currency-adjusted +1 percent). In the wholesale business it rose by three percent (currency-adjusted +9 percent).